File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of small testicular masses: outcomes from a single-centre specialist multidisciplinary team

TitleManagement of small testicular masses: outcomes from a single-centre specialist multidisciplinary team
Authors
Keywords#TesticularCancer
#tscsm
#uroonc
frozen section examination
radical orchidectomy
small testicular masses
surveillance
testicular biopsy
testicular cancer
Issue Date2023
Citation
BJU International, 2023, v. 131, n. 1, p. 73-81 How to Cite?
AbstractObjectives: To report the management outcomes of men with ≤20-mm small testicular masses (STMs) and to identify clinical and histopathological factors associated with malignancy. Patients and methods: A retrospective analysis of men managed at a single centre between January 2010 and December 2020 with a STM ≤20 mm in size was performed. Results: Overall, 307 men with a median (interquartile range [IQR]) age of 36 (30–44) years were included. Of these, 161 (52.4%), 82 (26.7%), 62 (20.2%) and 2 men (0.7%) underwent surveillance with interval ultrasonography (USS), primary excisional testicular biopsy (TBx) or primary radical orchidectomy (RO), or were discharged, respectively. The median (IQR) surveillance duration was 6 (3–18) months. The majority of men who underwent surveillance had lesions <5 mm (59.0%) and no lesion vascularity (67.1%) on USS. Thirty-three (20.5%) men undergoing surveillance had a TBx based on changes on interval USS or patient choice; seven (21.2%) were found to be malignant. The overall rate of malignancy in the surveillance cohort was 4.3%. The majority of men who underwent primary RO had lesions ≥10 mm (85.5%) and the presence of vascularity (61.7%) on USS. Nineteen men (23.2%) who underwent primary TBx (median lesion size 6 mm) had a malignancy confirmed on biopsy and underwent RO. A total of 88 men (28.7%) underwent RO, and malignancy was confirmed in 73 (83.0%) of them. The overall malignancy rate in the whole STM cohort was 23.8%. Malignant RO specimens had significantly larger lesion sizes (median [IQR] 11 [8–15] mm, vs benign: median [IQR] 8 [5–10] mm; P = 0.04). Conclusions: Small testicular masses can be stratified and managed based on lesion size and USS features. The overall malignancy rate in men with an STM was 23.8% (4.3% in the surveillance group). Surveillance should be considered in lesions <10 mm in size, with a TBx or frozen-section examination offered prior to RO in order to preserve testicular function.
Persistent Identifierhttp://hdl.handle.net/10722/328838
ISSN
2023 Impact Factor: 3.7
2023 SCImago Journal Rankings: 1.337
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWardak, Shafi-
dc.contributor.authorPang, Karl H.-
dc.contributor.authorCastiglione, Fabio-
dc.contributor.authorLindsay, Jamie-
dc.contributor.authorWalkden, Miles-
dc.contributor.authorHo, Dan Heffernan-
dc.contributor.authorKirkham, Alex-
dc.contributor.authorHadway, Paul-
dc.contributor.authorNigam, Raj-
dc.contributor.authorRees, Rowland-
dc.contributor.authorAlifrangis, Constantine-
dc.contributor.authorAlnajjar, Hussain M.-
dc.contributor.authorMuneer, Asif-
dc.date.accessioned2023-07-22T06:24:30Z-
dc.date.available2023-07-22T06:24:30Z-
dc.date.issued2023-
dc.identifier.citationBJU International, 2023, v. 131, n. 1, p. 73-81-
dc.identifier.issn1464-4096-
dc.identifier.urihttp://hdl.handle.net/10722/328838-
dc.description.abstractObjectives: To report the management outcomes of men with ≤20-mm small testicular masses (STMs) and to identify clinical and histopathological factors associated with malignancy. Patients and methods: A retrospective analysis of men managed at a single centre between January 2010 and December 2020 with a STM ≤20 mm in size was performed. Results: Overall, 307 men with a median (interquartile range [IQR]) age of 36 (30–44) years were included. Of these, 161 (52.4%), 82 (26.7%), 62 (20.2%) and 2 men (0.7%) underwent surveillance with interval ultrasonography (USS), primary excisional testicular biopsy (TBx) or primary radical orchidectomy (RO), or were discharged, respectively. The median (IQR) surveillance duration was 6 (3–18) months. The majority of men who underwent surveillance had lesions <5 mm (59.0%) and no lesion vascularity (67.1%) on USS. Thirty-three (20.5%) men undergoing surveillance had a TBx based on changes on interval USS or patient choice; seven (21.2%) were found to be malignant. The overall rate of malignancy in the surveillance cohort was 4.3%. The majority of men who underwent primary RO had lesions ≥10 mm (85.5%) and the presence of vascularity (61.7%) on USS. Nineteen men (23.2%) who underwent primary TBx (median lesion size 6 mm) had a malignancy confirmed on biopsy and underwent RO. A total of 88 men (28.7%) underwent RO, and malignancy was confirmed in 73 (83.0%) of them. The overall malignancy rate in the whole STM cohort was 23.8%. Malignant RO specimens had significantly larger lesion sizes (median [IQR] 11 [8–15] mm, vs benign: median [IQR] 8 [5–10] mm; P = 0.04). Conclusions: Small testicular masses can be stratified and managed based on lesion size and USS features. The overall malignancy rate in men with an STM was 23.8% (4.3% in the surveillance group). Surveillance should be considered in lesions <10 mm in size, with a TBx or frozen-section examination offered prior to RO in order to preserve testicular function.-
dc.languageeng-
dc.relation.ispartofBJU International-
dc.subject#TesticularCancer-
dc.subject#tscsm-
dc.subject#uroonc-
dc.subjectfrozen section examination-
dc.subjectradical orchidectomy-
dc.subjectsmall testicular masses-
dc.subjectsurveillance-
dc.subjecttesticular biopsy-
dc.subjecttesticular cancer-
dc.titleManagement of small testicular masses: outcomes from a single-centre specialist multidisciplinary team-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/bju.15874-
dc.identifier.pmid35986901-
dc.identifier.scopuseid_2-s2.0-85138321741-
dc.identifier.volume131-
dc.identifier.issue1-
dc.identifier.spage73-
dc.identifier.epage81-
dc.identifier.eissn1464-410X-
dc.identifier.isiWOS:000855734400001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats